1. History andintroduction of Dong A pharmaceutical
Dong-A Pharmaceutical isthe leading pharmaceutical company in Korea. Dong-A stands at the forefront of Korea's pharmaceutical industry; motivated by its respect for life and health to continuously innovate and develop products that enhance people's quality of life. We are working hard to grow internationally and become one ofthe world's most
to absorb bodily fluid. The most common type in daily use (andthetopic ofthe remainder of this article) is a usually disposable plug that is designed to be inserted intothe vagina during menstruation to absorb the flow of blood.
The Korean tampon market does not have a long history. Tempo was launched inthe Korean market as a first tampon product by Dongah in 2001. After that, Playtex, t
the two CEO affected the establishment of early CJ’s organizational structure and culture. First, the vice president of CJ, Son Gyeong-sik, is a person who always supports workers. His leadership style may be compared to iron handin a velvet glove. This kind of leadership style played a role in making internal cohesion. For example, although he does not order his employees directly, he hasthe
in Korea are most likely to be called Tempo since the name recognition of product is high - 78 percent of Koreans who recognize tampons call it Tempo based on the research done by Yuhan-Kimberly. However, according to Korean sanitary product market research, Tempo is at the 9th place followed by Playtex, world leading tampon. Tempo has 3 kinds- junior, regular, and super. While junior and regular
to prescription drugs to health
Products : Drugs, Vitamins, Minerals, Hygienic Drinks, Tonic Drinks, Mixed Drinks … …
Revenue : \ 2,762 (2008)
Net income : \ 214 (2008)
Employees : 739 (2009.06)
Homepage : http://www.ekdp.com/
광동제약 (주)
The logo of Kwang Dong imaged after a turtle implies the following Persistent action Unwavering self-confidence and judgment in reso
to KGMP. These efforts has made Hanmi one ofthe leading and promising pharmaceutical companies in Korea. So, Hanmi has showed continuous annual growth of 20%~30% since its establishment in 1973. Andin 2003, its amount oftotal sales was nearly 243 billion won.
In 2000, all Korean pharmaceutical companies confronted radical change oftheir business environment. The change is ‘the separation
inthe world.
- Leadership: The courage to shape a better future
- Collaboration: Leverage collective genius
- Integrity: Be real
- Accountability: If it isto be, it's up to me
- Passion: Committed in heart and mind
- Diversity: As inclusive as our brands
- Quality: What we do, we do well
(3) History
OF A REFRESHING IDEA>
The product that has given the world its be
the expiry ofthe original patent. It means that bio-similar copied original medicine’s quality, effect and safety. Also as bio-similar copied original one, its price is much cheaper than the origin. Bio medicine is effective andhas small side effect than chemical medicine. But people can’t get intouch with bio medicine because it istoo expensive. In this view, bio-similar contributed to a
is also expected toincrease.
The medical device industry in China was valued at $15 billionin 2009, accounting for more than 5% of global medical device industry and by 2016, due totheincrease in patient pool and improving healthcare infrastructure, there will be an increase in health expenses and awareness and affordability up to $25 billion.
Currently, developed country has ratio of
of
new entrance High There are still many entry barriers
Such as high capitalization, regulations, big firms inindustry with patents
+Prescription requirement regulations.
Bargaining
Power of suppliers
Low Components ofpharmaceutical product is not valuable, inexpensive, easy to get.
Bargaining
Power of buyers
Low Before the prescription regulati